{"altmetric_id":2650074,"counts":{"readers":{"mendeley":88,"citeulike":0,"connotea":0},"blogs":{"unique_users_count":2,"unique_users":[51890,55963],"posts_count":2},"news":{"unique_users_count":1,"unique_users":["bioportfolio"],"posts_count":1},"total":{"posts_count":17},"f1000":{"unique_users_count":1,"unique_users":["F1000Prime"],"posts_count":1},"twitter":{"unique_users_count":12,"unique_users":["TheLancetNeuro","NatRevNeurol","DrDanielKantor","DrKantor","FLneurology","Neurologique","MSclerosisNews","hugh_kearney","DrWBRO","APR_300","jpmarre","yassermetwally"],"posts_count":13}},"selected_quotes":["#MSresearch: Read the TOPIC trial","Oral teriflunomide provides benefits for patients with early multiple sclerosis, phase 3 trial reveals","Oral teriflunomide provides benefits for patients with early #MS phase 3 trial reveals","#Teriflunomide reduces risk of a second attack and new T2 brain lesions in high-risk #CIS patient"],"citation":{"altmetric_jid":"4f6fa4f73cf058f610002fd0","authors":["Aaron E Miller","Jerry S Wolinsky","Ludwig Kappos","Giancarlo Comi","Mark S Freedman","Tomas P Olsson","Deborah Bauer","Myriam Benamor","Philippe Truffinet","Paul W O'Connor"],"doi":"10.1016\/s1474-4422(14)70191-7","first_seen_on":"2014-09-04T01:27:25+00:00","issns":["14744422","1474-4422"],"journal":"Lancet Neurology","last_mentioned_on":1413273540,"links":["http:\/\/www.thelancet.com\/journals\/laneur\/article\/PIIS1474-4422(14)70191-7\/abstract?rss=yes","http:\/\/www.thelancet.com\/journals\/laneur\/article\/PIIS1474-4422%2814%2970191-7\/abstract?rss=yes","http:\/\/www.thelancet.com\/journals\/laneur\/article\/PIIS1474-4422%2814%2970191-7\/abstract","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25192851","http:\/\/dx.doi.org\/10.1016\/S1474-4422(14)70191-7","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25192851"],"pmid":"25192851","pubdate":"2014-10-01T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Neurosciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["neurology"],"title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/oral-teriflunomide-patients-first-clinical-episode-suggestive-multiple-sclerosis-topic-randomised-do"},"altmetric_score":{"score":29.162,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":29.162},"context_for_score":{"all":{"total_number_of_other_articles":8059538,"mean":6.8397725663364,"rank":288146,"this_scored_higher_than_pct":96,"this_scored_higher_than":7771404,"rank_type":"exact","sample_size":8059538,"percentile":96},"similar_age_3m":{"total_number_of_other_articles":187788,"mean":7.7624091124521,"rank":8671,"this_scored_higher_than_pct":95,"this_scored_higher_than":179116,"rank_type":"exact","sample_size":187788,"percentile":95},"this_journal":{"total_number_of_other_articles":1901,"mean":17.640816842105,"rank":223,"this_scored_higher_than_pct":88,"this_scored_higher_than":1678,"rank_type":"exact","sample_size":1901,"percentile":88},"similar_age_this_journal_3m":{"total_number_of_other_articles":39,"mean":29.268210526316,"rank":11,"this_scored_higher_than_pct":71,"this_scored_higher_than":28,"rank_type":"exact","sample_size":39,"percentile":71}}},"demographics":{"poster_types":{"member_of_the_public":4,"researcher":3,"practitioner":2,"science_communicator":3},"users":{"twitter":{"cohorts":{"Science communicators (journalists, bloggers, editors)":3,"Members of the public":4,"Scientists":3,"Practitioners (doctors, other healthcare professionals)":2}},"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":7,"Librarian":2,"Student  > Doctoral Student":8,"Researcher":17,"Student  > Ph. D. Student":12,"Student  > Postgraduate":11,"Student  > Master":5,"Other":13,"Student  > Bachelor":5,"Lecturer > Senior Lecturer":4,"Professor":3},"by_discipline":{"Medicine and Dentistry":58,"Neuroscience":7,"Psychology":5,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":8,"Computer Science":1,"Nursing and Health Professions":2,"Unspecified":3,"Pharmacology, Toxicology and Pharmaceutical Science":3}}},"geo":{"twitter":{"GB":2,"US":4,"IE":1,"FR":1,"EG":1},"mendeley":{"CA":1,"AT":1,"KR":1,"US":2,"IE":1,"ZA":1,"PT":1,"ES":3}}},"posts":{"news":[{"title":"Articles Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis TOPIC a randomised doubleblind placebocontrolled phase 3 trial","url":"http:\/\/www.bioportfolio.com\/news\/article\/2052523\/Articles-Oral-teriflunomide-for-patients-with-a-first-clinical-episode-suggestive-of.html","license":"public","citation_ids":[2650074],"posted_on":"2014-09-04T00:03:03+00:00","summary":"TOPIC is to our knowledge the first study to report benefits of an available oral diseasemodifying therapy in patients with early multiple sclerosis. These results extend the stages of multiple sclerosis in which teriflunomide shows a beneficial effect.","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}}],"twitter":[{"url":"https:\/\/twitter.com\/TheLancetNeuro\/status\/507595041162801153","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-04T18:24:23+00:00","author":{"name":"Lancet Neurology","url":"http:\/\/www.thelancet.com\/journals\/laneur","image":"https:\/\/pbs.twimg.com\/profile_images\/441610456797421568\/rlB679dH_normal.jpeg","description":"The Lancet Neurology is the leading clinical neurology journal publishing articles & reviews that advocate change in, or illuminate, clinical practice.","id_on_source":"TheLancetNeuro","tweeter_id":"2375597690","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":9918},"tweet_id":"507595041162801153"},{"url":"https:\/\/twitter.com\/NatRevNeurol\/status\/507463368605585409","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-04T09:41:09+00:00","author":{"name":"Nat Rev Neurology","url":"http:\/\/www.nature.com\/nrneurol\/","image":"https:\/\/pbs.twimg.com\/profile_images\/1629167444\/nrneurol_Twitter_logo_normal.jpg","description":"Nature Reviews Neurology is a clinical review journal from Nature Publishing Group. Follow us for the latest updates in neurology from the journal and beyond.","id_on_source":"NatRevNeurol","tweeter_id":"407766714","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":14722},"tweet_id":"507463368605585409"},{"url":"https:\/\/twitter.com\/DrDanielKantor\/status\/507788776731848704","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-05T07:14:13+00:00","author":{"name":"Daniel Kantor","url":"http:\/\/www.KantorNeurology.com","image":"https:\/\/pbs.twimg.com\/profile_images\/701963356165554176\/ghjkK8ee_normal.jpg","description":"Please visit:    https:\/\/twitter.com\/KantorNeurology    http:\/\/facebook.com\/KantorNeurology","id_on_source":"DrDanielKantor","tweeter_id":"100037560","geo":{"lt":26.25175,"ln":-80.17894,"country":"US"},"followers":475},"tweet_id":"507788776731848704"},{"url":"https:\/\/twitter.com\/DrKantor\/status\/507788777369374720","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-05T07:14:13+00:00","author":{"name":"Daniel Kantor","url":"http:\/\/www.KantorNeurology.com","image":"https:\/\/pbs.twimg.com\/profile_images\/701965143782121472\/ixhsN_Pu_normal.jpg","description":"Please visit:   https:\/\/twitter.com\/KantorNeurology http:\/\/facebook.com\/KantorNeurology","id_on_source":"DrKantor","tweeter_id":"132036219","geo":{"lt":26.25175,"ln":-80.17894,"country":"US"},"followers":362},"tweet_id":"507788777369374720"},{"url":"https:\/\/twitter.com\/FLneurology\/status\/507788777973374976","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-05T07:14:13+00:00","author":{"name":"FSN","url":"http:\/\/fsn.aan.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1219207379\/FSN_logo_normal.jpg","description":"The Florida Society of Neurology serves FL neurologists and their patients.\r\n\r\nJoin Today at http:\/\/floridaneurology.org","id_on_source":"FLneurology","tweeter_id":"239913828","geo":{"lt":"27.7567667","ln":"-81.4639835","country":"US"},"followers":74},"tweet_id":"507788777973374976"},{"url":"https:\/\/twitter.com\/Neurologique\/status\/507788784860430336","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-05T07:14:15+00:00","author":{"name":"KantorNeurology","url":"http:\/\/www.KantorNeurology.com","image":"https:\/\/pbs.twimg.com\/profile_images\/701960743424565249\/WTUE5RC1_normal.jpg","description":"Daniel Kantor, MD, FAAN now practices at Kantor Neurology in South Florida. He specializes in Multiple Sclerosis (MS), Migraine\/Headache and Concussion.","id_on_source":"Neurologique","tweeter_id":"42682461","geo":{"lt":39.76,"ln":-98.5,"country":"US"},"followers":823},"tweet_id":"507788784860430336"},{"url":"https:\/\/twitter.com\/TheLancetNeuro\/status\/507857299252056064","license":"datasift","rt":["DrDanielKantor"],"citation_ids":[2650074],"posted_on":"2014-09-05T11:46:30+00:00","author":{"name":"Lancet Neurology","url":"http:\/\/www.thelancet.com\/journals\/laneur","image":"https:\/\/pbs.twimg.com\/profile_images\/441610456797421568\/rlB679dH_normal.jpeg","description":"The Lancet Neurology is the leading clinical neurology journal publishing articles & reviews that advocate change in, or illuminate, clinical practice.","id_on_source":"TheLancetNeuro","tweeter_id":"2375597690","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":9918},"tweet_id":"507857299252056064"},{"url":"https:\/\/twitter.com\/MSclerosisNews\/status\/509063170149736448","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-08T19:38:12+00:00","author":{"name":"MS & Myelin Research","image":"http:\/\/pbs.twimg.com\/profile_images\/2324863866\/xeb9d3iusmwlbswyzik9_normal.jpeg","description":"Posting the latest news on #MultipleSclerosis, neurodegeneration & myelin biogenesis research. PhD in Neuroscience, communications enthusiast.","id_on_source":"MSclerosisNews","tweeter_id":"613274983","followers":2459},"tweet_id":"509063170149736448"},{"url":"https:\/\/twitter.com\/hugh_kearney\/status\/507497180341739521","license":"datasift","rt":["NatRevNeurol"],"citation_ids":[2650074],"posted_on":"2014-09-04T11:55:31+00:00","author":{"name":"Hugh Kearney","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000660294331\/2d80070808eb0057fff0854a9fd96fe3_normal.jpeg","description":"Neuropathology Fellow in molecular pathology, Beaumont Hospital. Multiple Sclerosis (MS) researcher.","id_on_source":"hugh_kearney","tweeter_id":"619101398","geo":{"lt":53.33306,"ln":-6.24889,"country":"IE"},"followers":202},"tweet_id":"507497180341739521"},{"url":"https:\/\/twitter.com\/DrWBRO\/status\/508905810752466946","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-08T09:12:54+00:00","author":{"name":"Wallace Brownlee","image":"https:\/\/pbs.twimg.com\/profile_images\/451750003229220864\/IESF_2f3_normal.jpeg","description":"Neurologist, National Hospital @UCLH and Hertford @ENHerts. MS Researcher, Queen Square MS Centre @QSMSCentre. Social media editor MSJ @MSJ_research","id_on_source":"DrWBRO","tweeter_id":"123682693","geo":{"lt":null,"ln":null},"followers":384},"tweet_id":"508905810752466946"},{"url":"https:\/\/twitter.com\/APR_300\/status\/508919735556513792","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-08T10:08:14+00:00","author":{"name":"Ariadna P\u00e9rez Ricart","url":"http:\/\/about.me\/ariadna.perez.ricart","image":"https:\/\/pbs.twimg.com\/profile_images\/536623125392154626\/bY1qnZ1g_normal.jpeg","description":"Farmac\u00e8utica hospital\u00e0ria interessada en Actualitzaci\u00f3 Farmacoterap\u00e8utica en Esclerosi M\u00faltiple","id_on_source":"APR_300","tweeter_id":"2159423424","geo":{"lt":null,"ln":null},"followers":60},"tweet_id":"508919735556513792"},{"url":"https:\/\/twitter.com\/jpmarre\/status\/514352777393602560","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-23T09:57:13+00:00","author":{"name":"md-fm.com","url":"http:\/\/www.md-fm.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2279054607\/oglf0x5dx2398lwk3a8r_normal.jpeg","description":"Medical News from around the world with MD-FM.","id_on_source":"jpmarre","tweeter_id":"45123692","geo":{"lt":46,"ln":2,"country":"FR"},"followers":55},"tweet_id":"514352777393602560"},{"url":"https:\/\/twitter.com\/yassermetwally\/status\/507308686197678080","license":"datasift","citation_ids":[2650074],"posted_on":"2014-09-03T23:26:30+00:00","author":{"name":"Professor Yasser","url":"http:\/\/yassermetwally.com","image":"http:\/\/pbs.twimg.com\/profile_images\/1233555507\/avatar_normal.jpg","description":"Professor of neurology","id_on_source":"yassermetwally","tweeter_id":"18056466","geo":{"lt":"30.0488185","ln":"31.2436663","country":"EG"},"followers":59},"tweet_id":"507308686197678080"}],"blogs":[{"title":"Treatment as Onset can slow development of MS","url":"http:\/\/multiple-sclerosis-research.blogspot.com\/2014\/09\/treatment-as-onset-can-slow-development.html","citation_ids":[2650074,2095037],"posted_on":"2014-09-22T06:00:00+00:00","summary":"Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS,  Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; for the TOPIC  Study Group.&nbsp;Oral  teriflunomide for patients with a first clinical episode suggestive of  multiple sclerosis(TOPIC): a ran","author":{"name":"Multiple Sclerosis Research","url":"http:\/\/multiple-sclerosis-research.blogspot.com\/","description":"A blog for people with MS and their families, by Barts and The London School of Medicine and Dentistry."}},{"title":"Teriflunomide geschikt bij vroege MS","url":"http:\/\/www.msweb.nl\/therapeutisch\/4421","citation_ids":[2650074],"posted_on":"2014-10-14T07:59:00+00:00","summary":"Teriflunomide pillen (Aubagio) verminderen de kans op een volgende schub bij mensen die nog maar &eacute;&eacute;n aanval hebben gehad en daarom de diagnose &lsquo;vermoedelijk MS&rsquo; hebben.","author":{"name":"MSweb RSS Feed","url":"http:\/\/www.msweb.nl\/","description":"MSweb - DE website over multiple sclerose"}}],"f1000":[{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/718634927","license":"public","citation_ids":[2650074],"posted_on":"2014-10-03T00:00:00+00:00","f1000_classes":["confirmation","good_for_teaching"],"f1000_score":"2"}]}}